- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07357428
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI) (CONNECT-ONE)
April 9, 2026 updated by: Paradromics
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI) to Provide Human Connection Through Communication
The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI).
The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with impaired communication as a result of severe loss of voluntary motor control; and (2) to provide control of computer devices for individuals with severe loss of voluntary motor control of the upper extremity.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
2
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Paradromics Clinical Team
- Phone Number: (512) 559 4120
- Email: clinical-team@paradromics.com
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- University of California, Davis
-
Contact:
- David Brandman M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Daniel Rubin, M.D., Ph.D.
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Contact:
- Matthew Willsey, M.D,. P.h.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Clinical diagnosis of a progressive neuromuscular disease or a neurological injury.
- Clinical diagnosis of anarthria or severe dysarthria.
- Wheelchair dependent with severely impaired upper limb function.
- Has a reliable method of communication and the ability to read and understand the English language.
- Has a study care partner (e.g. caregiver or multiple caregivers) for the duration of the study.
- Lives within a 4-hour radius of a study site.
Exclusion Criteria:
- Cognitive impairment or psychiatric illness that could impact the ability to comply with study requirements, as determined by the Study Investigator.
- Co-morbidities or an ongoing chronic medical condition that would impair the ability to comply with study requirements.
- The presence of another implanted device, like a pacemaker, deep brain stimulator, or implantable pulse generator.
- Requires, or is expected to require regular MRI scans for on-going medical conditions.
- In the opinion of the Study Investigator, the patient is not an appropriate candidate for the study, for reasons that could place the patient at undue risk or otherwise result in non-compliance with the study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Connect-One
|
The Connexus Brain Computer Interface is an implantable brain-computer interface.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary Safety: Number of Subjects With Device Related Adverse Events
Time Frame: Up to 12 months post-implant
|
Device Related Adverse Events: Number of subjects with device-related adverse events
|
Up to 12 months post-implant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Long-Term Safety: Number of Subjects With Device Related Adverse Events
Time Frame: Up to 6 years post-implant
|
Device Related Adverse Events: Number of subjects with device-related adverse events
|
Up to 6 years post-implant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2026
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
January 1, 2032
Study Registration Dates
First Submitted
December 23, 2025
First Submitted That Met QC Criteria
January 20, 2026
First Posted (Actual)
January 22, 2026
Study Record Updates
Last Update Posted (Actual)
April 14, 2026
Last Update Submitted That Met QC Criteria
April 9, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Neurobehavioral Manifestations
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Motor Neuron Disease
- Communication Disorders
- Paralysis
- Language Disorders
- Speech Disorders
- Articulation Disorders
- Pathological Conditions, Signs and Symptoms
- Behavior
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Communication
- Verbal Behavior
- Stroke
- Amyotrophic Lateral Sclerosis
- Quadriplegia
- Neuromuscular Diseases
- Dysarthria
- Speech
Other Study ID Numbers
- PRT-1014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
Fondazione Don Carlo Gnocchi OnlusScuola Superiore Sant'Anna di Pisa; Fondazione Policlinico Universitario Campus...Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke IschemicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
Clinical Trials on Connexus Brain-Computer Interface
-
Instituto Nacional de RehabilitacionNational Council of Science and Technology, Mexico; Hospital General Dr. Manuel... and other collaboratorsCompletedStroke | Stroke, IschemicMexico
-
Instituto Nacional de RehabilitacionInstituto Tecnologico y de Estudios Superiores de MontereyRecruitingCervical Spinal Cord InjuryMexico
-
Centre d'Investigation Clinique et Technologique...Association Française contre les Myopathies (AFM), ParisCompletedCommunication | Neuromuscular DiseaseFrance
-
Duke-NUS Graduate Medical SchoolSingapore General Hospital; Tan Tock Seng Hospital; National University, Singapore and other collaboratorsCompletedDementia | Mild Cognitive Impairment | Alzheimer's Disease | Age-Related Cognitive DeclineSingapore
-
Chinese University of Hong KongUnknown
-
Duke-NUS Graduate Medical SchoolNanyang Technological UniversityActive, not recruiting
-
National Healthcare Group, SingaporeDuke-NUS Graduate Medical School; Agency for Science, Technology and Research; Singapore Clinical Research InstituteCompletedAttention Deficit Hyperactivity DisorderSingapore
-
University of MichiganEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedHealthyUnited States
-
Duke-NUS Graduate Medical SchoolSingapore General Hospital; Agency for Science, Technology and Research; Singapore... and other collaboratorsCompletedDementia | Mild Cognitive Impairment | Alzheimer's Disease | Age-Related Cognitive DeclineSingapore
-
King's College LondonNot yet recruitingConversion Disorder | Functional Neurological Disorder | Functional Neurological Disorders | Conversion Disorder With Weakness/Paralysis